Thoracic Malignancy

2020. Technology appraisal guidance (NICE) 

NICE technology appraisals on chemotherapy for lung cancer

2019. Lung cancer: diagnosis and management (NICE)

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

2013. EGFR‑TK mutation testing locally advanced or metastatic NSCLC (NICE)

Epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing is indicated in adults with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). Patients with EGFR‑TK mutation-positive tumours gain more benefit from treatment with EGFR‑TK inhibitors than from standard chemotherapy treatment whereas patients mutation-negative tumours gain more benefit from standard chemotherapy than from EGFR‑TK inhibitors.

Leave a Reply

Your email address will not be published. Required fields are marked *